Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs
Medical
Pharma
Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.
Drugs
Health
Pharma
Sage Therapeutics halts trials of experimental drug to treat dementia
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Drugs
Health
Pharma
Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.
Drugs
Health
Pharma
Biogen’s ALS drug gets European Commission’s marketing nod
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs
Health
Pharma
European regulator backs Biogen’s drug for amyotrophic lateral sclerosis
HQ Team February 24, 2024: Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug.
Drugs
Health
Pharma
Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.
Drugs
Health
Pharma
Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s
HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.
Drugs
Health
Pharma
Biogen Inc. to buy US-based Reata Pharmaceuticals for $7.3 billion
HQ Team July 29, 2023: Biogen Inc., a US-based biotechnology company, will acquire Reata Pharmaceuticals for $7.3 billion to expand its neurological portfolio,.
